Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 3/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 1/20 | 1.00 |
| ▸ | PKM | P14618 | 1/20 | 1.00 |
| ▸ | ALOX15 | P16050 | 1/20 | 1.00 |
| ▸ | NFKB1 | P19838 | 1/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 1/20 | 1.00 |
| ▸ | MAPT | P10636 | 2/20 | 0.96 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.96 |
| ▸ | LMNA | P02545 | 2/20 | 0.96 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.96 |
| ▸ | BLM | P54132 | 1/20 | 0.96 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.96 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.59 |
| ▸ | DRD2 | P14416 | 1/20 | 0.55 |
| ▸ | DRD1 | P21728 | 1/20 | 0.55 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.55 |
| ▸ | SLC2A4 | P14672 | 1/20 | 0.55 |
| ▸ | IDO1 | P14902 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| 3-Hydroxybenzylhydrazine Dihydrochloride SCHEMBL29594115 | 1.00 | CYP3A4 (1.00) | CYP3A4CYP1A2PKMALOX15NFKB1 | |
| 3-Hydroxybenzylhydrazine Dihydrochloride SCHEMBL1309761 | 0.98 | MAPT (1.00) | CYP3A4CYP1A2PKMALOX15NFKB1 | |
| 3-Hydroxybenzylhydrazine Dihydrochloride SCHEMBL31298984 | 0.98 | MAPT (1.00) | CYP3A4CYP1A2PKMALOX15NFKB1 | |
| 3-Hydroxybenzylhydrazine Dihydrochloride SCHEMBL473713 | 0.98 | MAPT (1.00) | CYP3A4CYP1A2PKMALOX15NFKB1 | |
| 3-Hydroxybenzylhydrazine Dihydrochloride SCHEMBL31298981 | 0.98 | MAPT (1.00) | CYP3A4CYP1A2PKMALOX15NFKB1 | |
| 3-Hydroxybenzylhydrazine Dihydrochloride SCHEMBL23645200 | 0.91 | CYP3A4 (0.82) | CYP3A4CYP1A2PKMALOX15NFKB1 | |
| SCHEMBL28584924 | 0.84 | CYP3A4 (0.71) | CYP3A4CYP1A2PKMALOX15NFKB1 | |
| SCHEMBL14923237 | 0.83 | CYP3A4 (0.71) | CYP3A4CYP1A2PKMALOX15NFKB1 | |
| SCHEMBL9416529 | 0.82 | SLC2A4 (0.75) | CYP3A4CYP1A2PKMALOX15NFKB1 | |
| SCHEMBL6898308 | 0.80 | CYP3A4 (0.67) | CYP3A4CYP1A2PKMALOX15NFKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 639 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250032503-A1 | USE OF APREPITANT FOR TREATING ALZHEIMER'S DISEASE | HOTH THERAPEUTICS, INC. | 2025-01-30 | — | — | US | claimed |
| EP-4297868-A1 | USE OF APREPITANT FOR TREATING ALZHEIMER'S DISEASE | Hoth Therapeutics, Inc. (US) | 2024-01-03 | — | — | EP | claimed |
| WO-2023044463-A1 | SILK FIBROIN DERIVED BRUSH-LIKE POLYMERS | UNIVERSITY OF CONNECTICUT (US) | 2023-03-23 | — | — | WO | claimed |
| US-20230043198-A1 | MICROBIOTA METABOLITES THAT SHAPE HOST PHYSIOLOGY | YALE UNIVERSITY (US) | 2023-02-09 | — | — | US | claimed |
| WO-2022182658-A1 | USE OF APREPITANT FOR TREATING ALZHEIMER'S DISEASE | HOTH THERAPEUTICS, INC. (US) | 2022-09-01 | — | — | WO | claimed |
| US-11424006-B2 | Targeted drugs associated with trimethylamine and/or trimeihylamine-n-oxide | PSOMAGEN, INC. (US) | 2022-08-23 | — | — | US | claimed |
| EP-3893941-A1 | MICROBIOTA METABOLITES THAT SHAPE HOST PHYSIOLOGY | Yale University (US) | 2021-10-20 | — | — | EP | claimed |
| CN-113423436-A | Metabolites of microbial populations that shape host physiology | 耶鲁大学 | 2021-09-21 | — | — | CN | claimed |
| US-20210128498-A1 | TARGETED DRUGS ASSOCIATED WITH TRIMETHYLAMINE AND/OR TRIMETHYLAMINE-N-OXIDE | MACROGEN INC. (KR) | 2021-05-06 | — | — | US | claimed |
| EP-3668494-A1 | TARGETED DRUGS ASSOCIATED WITH TRIMETHYLAMINE AND/OR TRIMETHYLAMINE-N-OXIDE | Psomagen, Inc. (US) | 2020-06-24 | — | — | EP | claimed |
| US-20190050525-A1 | RIESKE-TYPE OXYGENASE/REDUCTASE TARGETED DRUGS FOR DIAGNOSTIC AND TREATMENT OF DISEASES | PSOMAGEN, INC. | 2019-02-14 | — | — | US | claimed |
| US-8324280-B2 | Treatment of prostate cancer with DDC inhibitor | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2012-12-04 | — | — | US | claimed |
| US-20100048709-A1 | Treatment of Prostate Cancer with DDC Inhibitor | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2010-02-25 | — | — | US | claimed |
| US-5240930-A | Yohimbine with catecholamine precursor | NATIONAL RESEARCH DEVELOPMENT CORPORATION (GB) | 1993-08-31 | — | — | US | claimed |
| US-5216019-A | Administering L-tryptophan and peripheral degradation inhibitor | KAMPRAD JOACHIM (DE) | 1993-06-01 | — | — | US | claimed |
| EP-0345304-B1 | PHARMACEUTICAL COMPOSITIONS | BTG INTERNATIONAL LIMITED (GB) | 1992-10-28 | — | — | EP | claimed |
| EP-0344158-B1 | PAIN-KILLER | KAMPRAD, Joachim (DE) | 1992-04-08 | — | — | EP | claimed |
| US-5015654-A | Pharmaceutical compositions | NATIONAL RESEARCH DEVELOPMENT CORPORATION (GB) | 1991-05-14 | — | — | US | claimed |
| EP-0344158-A1 | PAIN-KILLER. | KAMPRAD JOACHIM (DE) | 1989-12-06 | — | — | EP | claimed |
| WO-1988004170-A1 | PAIN-KILLER | KAMPRAD JOACHIM (DE) | 1988-06-16 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11424006-B2 | Targeted drugs associated with trimethylamine and/or trimeihylamine-n-oxide | PNMT, MAOA, HNMT | CYP3A4 103/4885CYP1A2 116/4885PKM 852/4885 |
| US-20210128498-A1 | TARGETED DRUGS ASSOCIATED WITH TRIMETHYLAMINE AND/OR TRIMETHYLAMINE-N-OXIDE | MAOA, PNMT, HNMT | CYP3A4 130/4885CYP1A2 69/4885PKM 1167/4885 |
| US-20250032503-A1 | USE OF APREPITANT FOR TREATING ALZHEIMER'S DISEASE | TACR1, ACHE, TACR2 | CYP3A4 2316/4885CYP1A2 1513/4885PKM 785/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.